sFT has been characterized as a possible biomarker for predicting the development of non-alcoholic fatty liver disease [100,101], type 2 diabetes mellitus [102], and obesity [103], and also for envisaging the progression of myalgic encephalomyelitis/chronic fatigue syndrome in COVID-19 patients [104]. The gene discussed is UBE2D1; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.